Log in

NASDAQ:VIVOMeridian Bioscience Stock Price, Forecast & News

$9.38
+0.60 (+6.83 %)
(As of 04/10/2020 04:39 AM ET)
Add
Compare
Today's Range
$8.66
Now: $9.38
$9.39
50-Day Range
$5.55
MA: $7.66
$9.38
52-Week Range
$5.51
Now: $9.38
$13.68
Volume453,700 shs
Average Volume695,025 shs
Market Capitalization$401.74 million
P/E Ratio20.39
Dividend YieldN/A
Beta0.34
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. Meridian Bioscience, Inc. was founded in 1976 and is headquartered in Cincinnati, Ohio.
Read More
Meridian Bioscience logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.8Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:VIVO
CUSIP58958410
Phone513-271-3700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$201.01 million
Cash Flow$0.99 per share
Book Value$4.47 per share

Profitability

Net Income$24.38 million

Miscellaneous

Employees585
Market Cap$401.74 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.


Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

How has Meridian Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Meridian Bioscience's stock was trading at $6.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VIVO stock has increased by 45.9% and is now trading at $9.38. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Meridian Bioscience?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Meridian Bioscience.

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Meridian Bioscience.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its earnings results on Friday, February, 7th. The company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.04. The business earned $47.42 million during the quarter, compared to analyst estimates of $48.71 million. Meridian Bioscience had a return on equity of 13.02% and a net margin of 9.70%. View Meridian Bioscience's earnings history.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its second quarter 2020 Pre-Market earnings guidance on Thursday, April, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $57-57 million, compared to the consensus revenue estimate of $49.3 million.

What price target have analysts set for VIVO?

3 brokers have issued twelve-month price objectives for Meridian Bioscience's stock. Their forecasts range from $8.00 to $11.00. On average, they expect Meridian Bioscience's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 1.3% from the stock's current price. View analysts' price targets for Meridian Bioscience.

What are Wall Street analysts saying about Meridian Bioscience stock?

Here are some recent quotes from research analysts about Meridian Bioscience stock:
  • 1. According to Zacks Investment Research, "Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis. " (11/3/2019)
  • 2. Canaccord Genuity analysts commented, "We reiterate our SELL rating and $9 PT on VIVO. Third straight miss. FQ3/19 revs of $48.4M (-6% Y/Y) missed our/Street’s prior $49.8M (-4%), driven by broad-based weakness. Diagnostics declined 9% (vs. our -6%) driven by a ~21% decline in molecular ~15% decline in gastrointestinal revs (volume declines in 13% decline in H. Pylori revs due to price erosion). Life Science revs declined 0.3% due to softness in the 9% decline in molecular reagents. (-350bps) missed our 59%E. Meridian manufactured" an EPS beat based on lower investment and lower commissions paid to sales reps who missed their numbers. Adj. EPS of $0.16 beat our $0.07/Street’s $0.09. Third straight guide down." (7/31/2019)

Has Meridian Bioscience been receiving favorable news coverage?

Media headlines about VIVO stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Meridian Bioscience earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutMeridian Bioscience.

Are investors shorting Meridian Bioscience?

Meridian Bioscience saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 1,221,500 shares, a decline of 13.4% from the February 27th total of 1,410,000 shares. Based on an average daily trading volume, of 860,400 shares, the days-to-cover ratio is currently 1.4 days. Approximately 2.9% of the company's stock are short sold. View Meridian Bioscience's Current Options Chain.

Who are some of Meridian Bioscience's key competitors?

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), Cara Therapeutics (CARA), Roku (ROKU), Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), NVIDIA (NVDA), Canopy Growth (CGC), General Electric (GE) and Amgen (AMGN).

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the following people:
  • Mr. John P. Kenny, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 50)
  • Ms. Susan D. Rolih, Consultant (Age 70)
  • Ms. Melissa A. Lueke, Consultant (Age 56)
  • Mr. Eric S. Rasmussen, Exec. VP & CFO (Age 51)
  • Mr. Bryan Baldasare, Chief Accounting Officer, Sr. VP, Corp. Controller & Treasurer

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.09%). Company insiders that own Meridian Bioscience stock include Bryan T Baldasare, David Phillips, Dwight E Ellingwood, Felicia Williams, James M Anderson, John Mccune Jr Rice, John Mcilwraith, John P Kenny and Lawrence Baldini. View institutional ownership trends for Meridian Bioscience.

Which institutional investors are buying Meridian Bioscience stock?

VIVO stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Meridian Bioscience stock in the last two years include Bryan T Baldasare, David Phillips, Dwight E Ellingwood, Felicia Williams, James M Anderson, John Mccune Jr Rice, John Mcilwraith, and John P Kenny. View insider buying and selling activity for Meridian Bioscience.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $9.38.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $401.74 million and generates $201.01 million in revenue each year. The company earns $24.38 million in net income (profit) each year or $0.68 on an earnings per share basis. Meridian Bioscience employs 585 workers across the globe. View additional information about Meridian Bioscience.

What is Meridian Bioscience's official website?

The official website for Meridian Bioscience is http://www.meridianbioscience.com/.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel